1-19 of 19
Sun Loo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemia

Sun Loo, Nicola Potter, Adam Ivey, Jenny O'Nions, Dr, Roderick Moon, Jelena Jovanovic, Chun Yew Fong, Natasha S Anstee, Ing S Tiong, Jad Othman, Chong Chyn Chua, Hannah Renshaw, Robert Baker, Shaun Fleming, Nigel H. Russell, David Ritchie, Ashish Bajel, Hsin-An Hou, Richard James Dillon, Andrew H. Wei
Journal: Blood
Blood blood.2024026605.
https://doi.org/10.1182/blood.2024026605
Published: 2024
Includes: Supplemental data
Journal Articles

How I Treat patients with AML using azacitidine and venetoclax

Andrew H. Wei, Sun Loo, Naval G Daver
Journal: Blood
Blood blood.2024024009.
https://doi.org/10.1182/blood.2024024009
Published: 2024
Includes: Supplemental data
Journal Articles

Molecular MRD is strongly prognostic in patients with NPM1 -mutated AML receiving venetoclax-based nonintensive therapy

Clinical Trials & Observations Brief Report
Jad Othman, Ing S. Tiong, Jenny O'Nions, Mike Dennis, Katya Mokretar, Adam Ivey, Michael Austin, Anne-Louise Latif, Mariam Amer, Wei Yee Chan, Charles Crawley, Francesca Crolla, Joe Cross, Ray Dang, Johnathon Elliot, Chun Y. Fong, Sofia Galli, Paolo Gallipoli, Francesca Hogan, Pallavi Kalkur, Anjum Khan, Pramila Krishnamurthy, John Laurie, Sun Loo, Scott Marshall, Priyanka Mehta, Vidhya Murthy, Sateesh Nagumantry, Srinivas Pillai, Nicola Potter, Rob Sellar, Tom Taylor, Rui Zhao, Nigel H. Russell, Andrew H. Wei, Richard Dillon
Journal: Blood
Blood (2024) 143 (4): 336–341.
https://doi.org/10.1182/blood.2023021579
Published: 2024
Includes: Supplemental data
Journal Articles

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG

Clinical Trials & Observations
Sun Loo, Andrew W. Roberts, Natasha S. Anstee, Glen A. Kennedy, Simon He, Anthony P. Schwarer, Anoop K. Enjeti, James D’Rozario, Paula Marlton, Ian A. Bilmon, John Taper, Gavin Cull, Campbell Tiley, Emma Verner, Uwe Hahn, Devendra K. Hiwase, Harry J. Iland, Nick Murphy, Sundra Ramanathan, John Reynolds, Doen Ming Ong, Ing Soo Tiong, Meaghan Wall, Michael Murray, Tristan Rawling, Joanna Leadbetter, Leesa Rowley, Maya Latimer, Sam Yuen, Stephen B. Ting, Chun Yew Fong, Kirk Morris, Ashish Bajel, John F. Seymour, Mark J. Levis, Andrew H. Wei
Journal: Blood
Blood (2023) 142 (23): 1960–1971.
https://doi.org/10.1182/blood.2023020301
Published: 2023
Includes: Supplemental data
Journal Articles

Pre-Transplant Measurable Residual Disease (MRD) Detection of KMT2A- rearranged Acute Myeloid Leukemia Is Strongly Associated with Inferior Post-Transplant Outcome

Sun Loo, Nicola Potter, Adam Ivey, Jenny O'Nions, Roderick Moon, Chun Yew Fong, Natasha Anstee, Ing Soo Tiong, Chong Chyn Chua, Jad Othman, Hannah Renshaw, Robert Baker, Nigel H. Russell, Ashish Bajel, Hsin-An Hou, Richard Dillon, Andrew H. Wei
Journal: Blood
Blood (2023) 142 (Supplement 1): 1577.
https://doi.org/10.1182/blood-2023-185541
Published: 2023
Journal Articles

Venetoclax Has Potent Efficacy in NPM1 mutated AML with Acquired Resistance Associated with Either Perturbed Pro-Survival Signalling or NPM1 wild-Type Populations

Chong Chyn Chua, Natasha Anstee, Christoffer Flensburg, Charis Teh, Adam Ivey, Noorul Amin, Rachel Thijssen, Stefan K. Bohlander, Purvi M. Kakadia, Zhen Xu, Chun Yew Fong, Stephen Ting, Sun Loo, Ing Soo Tiong, Daniel Gray, Shaun Fleming, Nadia Davidson, Andrew W. Roberts, Ian Majewski, Andrew H. Wei, Fiona C. Brown
Journal: Blood
Blood (2023) 142 (Supplement 1): 423.
https://doi.org/10.1182/blood-2023-185321
Published: 2023
Journal Articles

Pretransplant FLT3 -ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome

Sun Loo, Richard Dillon, Adam Ivey, Natasha S. Anstee, Jad Othman, Ing Soo Tiong, Nicola Potter, Jelena Jovanovic, Manohursingh Runglall, Chyn Chua Chong, Ashish Bajel, David Ritchie, Kelli Gray, Zhi Han Yeoh, Michelle McBean, Amanda Gilkes, Ian Thomas, Sean Johnson, Nigel H. Russell, Andrew H. Wei
Journal: Blood
Blood (2022) 140 (22): 2407–2411.
https://doi.org/10.1182/blood.2022016567
Published: 2022
Includes: Supplemental data
Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) and Impact on Clonal Haematopoiesis and Post-HCT Therapy-Related Myeloid Neoplasm in Heavily Treated and Poor Risk Patients with Plasma Cell Myeloma

Michael D Ashby, Natasha S Anstee, Tongted Das, Ing S Tiong, Sun Loo, Andrew Spencer, Andrew H. Wei
Journal: Blood
Blood (2022) 140 (Supplement 1): 2876–2878.
https://doi.org/10.1182/blood-2022-165544
Published: 2022
Journal Articles

ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial

Andrew H Wei, Harry J Iland, John Reynolds, Sun Loo, Chong Chyn Chua, David Westerman, Ing S Tiong, Adam Ivey, Piers Blombery, Natasha S Anstee, Rachel M Koldej, David J. Curtis, David Kipp, David Ritchie, David M Ross, Amanda Souza, Jenny Collins, Ashish Bajel, Carolyn Grove, Paula Marlton, Andrew W Roberts, Naveen Pemmaraju, Keyur P. Patel, Sanam Loghavi, Marina Konopleva, Naval Daver, Courtney D. DiNardo
Journal: Blood
Blood (2022) 140 (Supplement 1): 3341–3343.
https://doi.org/10.1182/blood-2022-167837
Published: 2022
Journal Articles

High Response and Prolonged Treatment-Free Remission after a Short-Course of Modified Intensive Chemotherapy and Venetoclax in Elderly AML: An Updated Analysis of the Caveat Trial

Chong Chyn Chua, Sun Loo, John Reynolds, Ing S Tiong, Chun Yew Fong, Stephen B Ting, Shaun Fleming, Andrew W Roberts, Andrew H Wei
Journal: Blood
Blood (2022) 140 (Supplement 1): 1708–1710.
https://doi.org/10.1182/blood-2022-165021
Published: 2022
Journal Articles

A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia

Ing S Tiong, Devendra Hiwase, Emad Uddin Abro, Ashish Bajel, Emma Palfreyman, Sun Loo, Shaun Fleming, Chun Yew Fong, Tse-Chieh Teh, Adam Ivey, Andrew H Wei
Journal: Blood
Blood (2022) 140 (Supplement 1): 1453–1455.
https://doi.org/10.1182/blood-2022-163041
Published: 2022
Journal Articles

A Phase-Ib/II Clinical Evaluation of Ponatinib in Combination with Azacitidine in FLT3 -ITD and CBL -Mutant Acute Myeloid Leukemia (PON-AZA study)

David Kipp, Sun Loo, Andrew Charles Perkins, Steven W Lane, Emily Blyth, Anoop Kumar Enjeti, Ashish Bajel, John Reynolds, Andrew H. Wei
Journal: Blood
Blood (2021) 138 (Supplement 1): 2350.
https://doi.org/10.1182/blood-2021-154247
Published: 2021
Journal Articles

High Sensitivity Detection of FLT3 -ITD Measurable Residual Disease By Deep Sequencing Prior to Hematopoietic Cell Transplant Is Highly Prognostic for Outcome in Acute Myeloid Leukemia

Sun Loo, Richard Dillon, Natasha S Anstee, Ing S Tiong, Adam Ivey, Nicola Potter, Jad Othman, Manohursingh Runglall, Jelena Jovanovic, Amanda Gilkes, Ian Thomas, Sean Johnson, Nigel H. Russell, Andrew H. Wei
Journal: Blood
Blood (2021) 138 (Supplement 1): 2364.
https://doi.org/10.1182/blood-2021-149301
Published: 2021
Journal Articles

A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia

Ing S Tiong, Sun Loo, Emad Uddin Abro, Devendra Hiwase, Shaun Fleming, Ashish Bajel, Emma Palfreyman, Chun Yew Fong, Tse-Chieh Teh, Adam Ivey, Andrew H. Wei
Journal: Blood
Blood (2021) 138 (Supplement 1): 1261.
https://doi.org/10.1182/blood-2021-152583
Published: 2021
Journal Articles

Allogeneic Hematopoietic Cell Transplantation Outcomes of Patients with R/R AML or Higher-Risk MDS Treated with the TIM-3 Inhibitor MBG453 (Sabatolimab) and Hypomethylating Agents

Andrew M. Brunner, Elie Traer, Norbert Vey, Sebastian Scholl, Natalia Tovar, Kimmo Porkka, Rupa Narayan, Guillermo Garcia-Manero, Steve Knapper, Martin Wermke, Jeroen J. Janssen, Jordi Esteve, Sun Loo, Mika Kontro, Zachariah Defilipp, Andrew H. Wei, Uma Borate
Journal: Blood
Blood (2021) 138 (Supplement 1): 3677.
https://doi.org/10.1182/blood-2021-151455
Published: 2021
Journal Articles

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study

Andrew M. Brunner, Jordi Esteve, Kimmo Porkka, Steve Knapper, Elie Traer, Sebastian Scholl, Guillermo Garcia-Manero, Norbert Vey, Martin Wermke, Jeroen Janssen, Rupa Narayan, Sun Loo, Mika Kontro, Oliver Ottmann, Purushotham Naidu, Marc Pelletier, May Han, Andrew Lewandowski, Na Zhang, Anisa Mohammed, Mikael L. Rinne, Uma Borate, Andrew H. Wei, Natalia Tovar
Journal: Blood
Blood (2021) 138 (Supplement 1): 244.
https://doi.org/10.1182/blood-2021-146039
Published: 2021
Journal Articles

Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose

Andrew H. Wei, MBBS, PhD, Jordi Esteve, Kimmo Porkka, Steve Knapper, Norbert Vey, MD, Sebastian Scholl, Guillermo Garcia-Manero, MD, Martin Wermke, Jeroen Janssen, Elie Traer, Sun Loo, Rupa Narayan, Natalia Tovar, Mika Kontro, Oliver Ottmann, Siyan Xu, Serena Liao, Andrew Stein, Fariba Khanshan, Purushotham Naidu, Na Zhang, Anisa Mohammed, Mikael L. Rinne, Haiying Sun, Andrew M. Brunner, MD, Uma Borate
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–42.
https://doi.org/10.1182/blood-2020-137307
Published: 2020
Journal Articles

Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

Andrew H Wei, MBBS, PhD, Glen A Kennedy, MBBS FRACP FRCPA, Kirk L Morris, MBBA, FRACP, FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Simon He, MBBS, FRACP, FRCPA, Anthony Schwarer, MBBS, MD FRACP, FRCPA, Stephen B Ting, MBBS, FRACP, FRCPA, PhD, Anoop Kumar Enjeti, MBBS,FRCPA, FRACP, PhD MD MRCP, Sam Yuen, MBBS, FRACP, FRCPA, James D'Rozario, MBBS, FRACP, FRCPA, Maya Latimer, MBBS, FRACP, FRCPA, Paula Marlton, MBBS FRACP FRCPA, Ian Bilmon, BMBS, FRACP, FRCPA, John Taper, MBBS, FRACP, FRCPA, B Pharm, Gavin Cull, MBBS, MD FRACP, FRCPA, Campbell Tiley, MBBS, FRACP, FRCPA, Emma Verner, MBBS, FRACP, FRCPA, Uwe H Hahn, MBBS, MD FRCPA, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Harry Iland, MBBS, FRACP, FRCPA, MHGSA, Nichloas Murphy, MBBS, FRACP, FRCPA, Sundra Ravanathan, MBBS, FRACP, FRCPA, RCPA, Uyen Nguyen, Doen Ming Ong, MBBS, FRACP, FRCPA, RCPA, Sun Loo, MBBS, FRACP, FRCPA, RCPA, Ing-Soo Tiong, MBBS, FRACP, FRCPA, RCPA, Meaghan Wall, MBBS, FRACP, FRCPA, RCPA, PhD, Natasha S Anstee, PhD, Mark Levis, MD PhD, Michael Murray, PhD DSc, Tristan Rawling, PhD, Joanna Leadbetter, PhD, Ashish Bajel, FRACP, Andrew W Roberts, MBBS
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–38.
https://doi.org/10.1182/blood-2020-137334
Published: 2020
Journal Articles

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study

Andrew M. Brunner, MD, Jordi Esteve, Kimmo Porkka, Steve Knapper, Norbert Vey, MD, Sebastian Scholl, Guillermo Garcia-Manero, MD, Martin Wermke, Jeroen Janssen, Elie Traer, Sun Loo, Rupa Narayan, Natalia Tovar, Mika Kontro, Oliver Ottmann, Purushotham Naidu, Sema Kurtulus, Jessica Makofske, Serena Liao, Anisa Mohammed, Catherine A. Sabatos-Peyton, Mikael L. Rinne, Uma Borate, Andrew H. Wei, MBBS, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–2.
https://doi.org/10.1182/blood-2020-136855
Published: 2020